Proteinuria due to non-steroid-responsive renal disease may be harmful. Firstly, because it may cause a nephrotic syndrome, and, secondly, because it is, like hypertension, associated with an increased risk of progressive renal damage and loss of renal function over the years. Until recently, only non-steroidal antiinflammatory drugs (NSAIDs) were available to reduce proteinuria in such patients. Due to their potential side-effects, however, NSAIDs have never been widely used as antiproteinuric agents. In 1985 some studies were published showing that inhibition of angiotensin-converting enzyme (ACE) not only reduced the elevated blood pressure in rats with chronic renal failure (experimentally induced by renal ablation or by induced diabetic nephropathy), but also prevented the development of glomerular damage with proteinuria and loss of renal function in these animals. This beneficial effect of ACE inhibition was attributed to the prevention of glomerular hypertension. At the same time it was reported that ACE inhibition could reduce proteinuria in patients with advanced diabetic nephropathy. ACE inhibitors might thus be an attractive alternative for NSAIDs as antiproteinuric treatment, possibly being renoprotective, and being generally well-tolerated.
ACE inhibition versus conventional antihypertensive treatment
The question was addressed whether ACE inhibition would reduce proteinuria in 13 hypertensive patients with renal disease of various origin. Whereas conventional antihypertensive treatment (usually triple therapy) had, retrospectively, no significant effect on urinary protein excretion, ACE inhibition with lisinopril reduced proteinuria by (mean) 61% after 12 weeks of treatment. This proteinuria-lowering effect did not correlate with the fall in blood pressure nor with the (mean) 21% reduction in glomerular filtration rate (GFR) during lisinopril, whereas it did correlate with both the fall in renal vascular resistance and in filtration fraction, suggesting a postglomerular vasodilation with a fall in glomerular filtration pressure as a cause for the antiproteinuric effect of the ACE inhibitor. 
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Angiotensin I1 Angiotensin-converting enzyme inhibitors Blood pressure Glomerular filtration rate Hemodynamics, renal Usinopril Nephrotic syndrome Proteinuria the blood pressure during ~-methyldopa, reduced proteinuria by 27%, while a lisinopril dose of 10 mg per day reduced proteinuria by 50%. This antiproteinuric effect of lisinopril occurred irrespective of initial proteinuria (ranging from 3.2 to 10.5 g per day), blood pressure (ranging from low-normal to elevated values), or renal function (with initial GFR ranging from 34 to 127 ml/min). In some patients it took several weeks before the proteinuria-lowering effect of the ACE inhibitor reached a maximum and stabilized. The antiproteinuric effect of lisinopril was abolished when the sodium intake was increased from 50 to 200 mmol per day during lisinopril treatment, and proteinuria fell again when dietary sodium restriction was re-instituted. The antiproteinuric effect of the higher dose of lisinopril (median 10 mg per day) was comparable to the reduction in proteinuria during 150 mg per day of indometacin. During indomethacin a reversible fall of 19% in GFR occurred, which was significantly more than the 7% decrease in GFR during lisinopril, and the patients experienced more side-effects during indomethacin intake than during lisinopril intake.
Thus, the antiproteinuric effect of the ACE inhibitor lisinopril .appears to be dose-and time-related, and was markedly dependent on dietary sodium restriction, whereas it did not depend on initial proteinuria, blood pressure, or renal function. The effect is comparable to that of indomethacin, while adverse effects were less.
230
Lisinopril versus indomethacin
The efficacy of the ACE inhibitor lisinopril in treating overt proteinuria was prospectively compared with that of the NSAID indomethacin in 12 patients with non-diabetic renal disease, who used a sodiumrestricted diet. Blood pressure lowering with c~-methyldopa in the control periods had no effect on urinary protein excretion. During 10-week treatment periods, a lisinopril dose of (median) 5 mg per day, resulting in a blood pressure that was comparable to
Additive effect in nephrotic syndrome
We subsequently studied the efficacy of the proteinuria-lowering effect of ACE inhibition in 10 diuretic-treated patients with the nephrotic syndrome (mean proteinuria 10.5 g per day), as well as the effect of the combination of the NSAID indomethacin and the ACE inhibitor lisinopril. Both indomethacin and lisinopril monotherapy lowered proteinuria by more than 50% in 2-month study periods, while combination therapy further reduced proteinuria to 
24-h Urinary protein excretion (bars; mean + SEM) in 10 diuretic-treated nephrotic patients in the different 2-month study periods; without therapy (control), during indomethacin, during combination of indomethacin and lisinopril, and during lisinopril. The line represents the mean and SEM of the corresponding glomerular filtration rate (GFR)
. *: P < 0.05; **: P < 0.01 as compared to the preceding study period patients. The decrease in GFR during ACE inhibition reflects that GFR is dependent on adequate efferent glomerular vasoconstriction in sodium-depleted patients with renal disease. This is similar to patients with bilateral renal artery stenosis who also may show a fall in GFR during ACE inhibition, that can also be modulated by changing the dose of the ACE inhibitor or the sodium balance of the patients. In both groups of patients (with proteinuric renal disease and with bilateral renal artery stenosis) the fall in blood pressure cannot be compensated for, as the renal autoregulation fails due to the preferential postglomerular vasodilation during ACE inhibition, resulting in a fall in glomerular filtration pressure and in GFR. In parallel to the effects on GFR, the effect of ACE inhibition on proteinuria is also influenced by the dose of the drug and the sodium balance 9 This favours the idea that the antiproteinuric effect of ACE inhibition is at least partially effected by a renal haemodynamic mechanism.
The possible role of renal haemodynamic changes in the antiproteinuric effect of ACE inhibition is further illustrated in different studies, showing a positive correlation between the reduction in proteinuria and the fall in filtration fraction which reflects a fall in glomerular filtration pressure during ACE inhibition. Diabetic and non-diabetic patients probably differ in response. In diabetics the lowering of the blood pressure as such seems to contribute more to the antiproteinuric (and possibly renoprotective) effect of ACE inhibition than in patients with nondiabetic renal disease. In the latter, blood pressure lowering as such is less effective and the characteristic renal haemodynamic effects of ACE inhibition seem to be of relatively more importance. less than 25% of the control values (Fig. 1 ) . Serum albumin rose during both monotherapies, without further increase on combination therapy 9 GFR showed a comparable reversible fall during indomethacin (of 15%) and lisinopril (of 12%) versus control. In parallel with the additive proteinuria-lowering effect, combination therapy of indomethacin and lisinopril also additively lowered GFR (by 27%; see Fig. 1 ). Severe hyperkalaemia (> 6.0 retool/I) occurred in 3 patients during combination therapy.
Thus, both indomethacin and lisinopril effectively reduced proteinuria in sodium-depleted patients with the nephrotic syndrome. Moreover, combining these drugs resulted in an additive antiproteinuric effect. This therapy may be useful in the symptomatic treatment of the nephrotic syndrome, but renal function and serum potassium should be monitored carefully.
More on the role of haemodynamics
Whereas, in general, no changes in serum creatinine are observed during treatment with an ACE inhibitor, we consistently detected a slight but significant decrease in GFR in the ACE inhibitor-treated patients with proteinuric renal disease. We showed that this effect of the ACF inhibitor on GFR is influenced by the dose of the drug and by the sodium balance of the
Preload and afterload reduction
The mechanism of the antiproteinuric effect of ACE inhibition was further studied by comparing the renal haemodynamic and antiproteinuric effects of indomethacin and lisinopril monotherapy and the combination of both drugs, in 9 patients with nondiabetic non-symptomatic proteinuric renal disease. The sequence of therapies was reversed in comparison to the study described above with symptomatic diuretic-treated nephrotic patients. Whereas both indomethacin and lisinopril lower urinary protein excretion, the haemodynamic profiles of these drugs appeared to be quite different: lisinopril lowered blood pressure and renal vascular resistance, inducing a fall in GFR while renal plasma flow was stable, which resulted in a fall in filtration fraction; indomethacin raised renal vascular resistance while GFR and renal plasma flow fell similarly, leaving the filtration fraction unchanged. Both haemodynamic profiles are compatible with a fall in intraglomerular capillary pressure: due to an afterload reduction by a preferentially postglomerular vasodilation during lisinopril, and due to a preload reduction by a preglomerular vasoconstriction during indomethacin. The antiproteinuric effect of both drugs can thus be attributed to a haemodynamic final common pathway, viz., the decrease in glomerular filtration pressure. In accordance with this assumption, during combination therapy we observed an additive decrease both in urinary protein excretion and in GFR, which were strongly correlated, presumably due to a simultaneous pre-and afterload reduction of the glomerular filtration pressure.
Changes in glomerular permselectivity
We also studied the qualitative changes in proteinuria during ACE inhibition, in addition to the quantitative changes as described previously comparing the effects of lisinopril with indomethacin. It appeared that, like indomethacin, the ACE inhibitor increased the selectivity of the residual proteinuria, since fractional renal clearances of proteins of greater molecular weight were more reduced during ACE inhibition than renal clearances of smaller proteins. This can be interpreted as an improvement in size permselectivity of the glomerular capillary barrier, due to the fall in intraglomerular filtration pressure or to inhibition of a direct effect of angiotensin II on the glomerular capillary filter. This increase in glomerular permselectivity may be part of the mechanism of the antiproteinuric effect of ACE inhibition.
The role of angiotensin II
We then studied the role of the hormone angiotensin II and the angiotensin II-mediated renal haemodynamic effects in the mechanism of the antiproteinuric effect of ACE inhibition. The effects of different doses of exogenous angiotensin II (5%, 10% and 20% of the pressor dose) on renal haemodynamics and urinary protein excretion were studied in 6 non-diabetic normotensive patients with a mean proteinuria of 7.5 g per 24 h, both before and after three months of treatment with the ACE inhibitor lisinopril. Lisinopril lowered proteinuria by more than 60% and induced a fall in blood pressure, renal vascular resistance and filtration fraction, whereas plasma angiotensin II levels and also angiotensin II pressor doses were unchanged as compared to the pretreatment values. Angiotensin I! infusion during 6 h induced characteristic effects which appeared to be similar before and during lisinopril treatment: a dose-related fall in renal plasma flow and rise in systemic blood pressure, renal vascular resistance and filtration fraction, while the glomerular filtration rate remained relatively stable. However, neither before nor during lisinopdl therapy did any change in urinary protein loss occur during the infusions of angiotensin II. Thus, despite the fact that angiotensin II reversed the long-term systemic and renal haemodynamic effects of lisinopril, the proteinuria-lowering effect of the ACE inhibitor was not reversed.
This observation argues against a direct relation between the inhibition of angiotensin II synthesis and the resulting renal haemodynamic effects (with a fall in glomerular filtration pressure) on the one hand, and the reduction in proteinuria on the other during ACE inhibition. We suggest that the long-term antiproteinuric effect of ACE inhibition may be the result of chronic haemodynamic effects causing structural changes that are not reversed by a short-term infusion of angiotensin II. Moreover, the inhibition of angiotensin II synthesis on the renal tissue level could play a role in the antiproteinuric effect of ACE inhibition, possibly through a non-haemodynamic mechanism of action.
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